Listen instead
At the Family Allergy and Asthma clinic, a medical assistant preparing to prescribe a high-cost biologic therapy faces a historically consistent obstacle. Internal industry data shows that approximately one in three patients prescribed these advanced treatments never actually receives their first dose. This abandonment is rarely clinical; instead, it is the result of a manual administrative gauntlet involving dozens of phone calls, faxes, and prior authorization forms. Rather than spending hours navigating this paperwork, the assistant now inputs the prescription into Forus, a software platform designed to automatically assign an artificial intelligence agent to manage the administrative journey from the clinic to the pharmacy.
Resolving the administrative bottleneck
This transition from manual paperwork to automated tracking represents a structural shift in how specialty clinics manage the logistics of complex prescriptions. To scale this infrastructure, Forus has secured 150 million dollars in a Series C funding round. The investment, led by Bain Capital Ventures, values the company at 3 billion dollars, according to statements from the firm. The transaction represents a threefold increase from the valuation established during its Series B round completed four months prior, bringing total funding to more than 300 million dollars.
Every institutional investor from previous rounds participated in this transaction, according to Bain Capital Ventures general partner Kevin Zhang. The participating firms include Thrive Capital, General Catalyst, Accel, Redpoint, and SV Angel. This capital concentration highlights investor interest in automated administrative platforms that target operational friction rather than purely clinical tools.
The platform operates by launching a dedicated software agent for each individual prescription. This agent navigates the distinct systems of insurance approvals, prior authorizations, financial assistance programs, and specialty pharmacies. Because the service is free for both healthcare providers and patients, Forus eliminates the financial friction that typically slows down the adoption of new software at the clinical level.
Proven clinical and operational impact
Operational data from clinical practices using the platform indicates a measurable reduction in administrative delays. At Family Allergy and Asthma, the practice reports that its median turnaround time for prior authorizations fell from more than seven days to 1.1 days after adopting the system. Similarly, administrators at DOCS Dermatology reported an 80 percent increase in the absolute number of patients who successfully initiated their prescribed specialty medications.
These clinical outcomes have accelerated the geographic expansion of the network. Forus reports that its platform is currently deployed by healthcare providers across all 50 states, reaching an estimated 85 percent of residential ZIP codes in the United States. In the company's initial medical specialty, more than one third of active providers nationwide have integrated the system into their daily workflows, according to internal company figures.
The scale of the network is further supported by direct integration with the pharmaceutical industry. Forus currently maintains partnerships with nine of the top 15 global biopharma companies. These direct integrations allow the software agents to coordinate manufacturer co-pay assistance and patient support programs directly inside the clinical workflow, bypassing the manual enrollment processes that historically delayed treatment.
The economics of free healthcare software
The decision to distribute the platform at no cost to clinics and patients is a strategic departure from traditional healthcare IT sales models. Historically, healthcare software vendors have struggled with multi-year sales cycles and low adoption rates because clinical practices operate on thin margins and resist new capital expenditures. By removing licensing and subscription fees, Forus bypasses these procurement hurdles entirely.
This distribution model is funded by the commercial incentives of biopharma companies. For pharmaceutical manufacturers, patient abandonment is a major financial drain. When one third of patients walk away from a prescribed therapy due to administrative delays, the manufacturer loses the lifetime value of that patient. By accelerating the administrative clearance process, Forus ensures that valid clinical decisions result in actual drug delivery, creating a direct financial return for the biopharma partners who fund the network.
The 3 billion dollar valuation suggests that institutional investors view the administrative layer of healthcare as a highly valuable market. Rather than attempting to change clinical decisions, the platform captures value by streamlining the execution of those decisions, proving that solving the logistics of delivery is just as critical as inventing the drug itself.
Source: The HealthTech Signal
